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Abstract
In this research, peptides and protein containing serine on the N-terminus underwent siteselective modification following organocatalyzed bioconjugation that offered an additional
functional group. It was shown that transforming the N-terminus serine to an aldehyde allowed
site-specific bioconjugation to occur by utilizing the well-known Henry reaction. This method also
grants a safer pathway for bioconjugation utilizing “green-chemistry” and biocompatible
conditions. Amino acids and amino acid derived organocatalysts were utilized in the Henry
reaction resulting in yields of up to 86 % conversion. Promising preliminary results were achieved
in this research using peptides and myoglobin as the bioconjugation targets. Further investigation
to be performed includes the analysis of the final product, as well as, applying this methodology
to a number of other proteins.
Keywords
Bioconjugation, organocatalyst, Henry reaction, protein modification, site-selective.
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Chapter 1: Introduction

Proteins are the backbone for many cellular functions as they take an array of roles
including building our immune system1, carrying out an array of reactions, sending messages from
cell-to-cell and transporting materials in-and-out of cells2,3, as well as build the structural
components in cells4. When proteins begin to miscommunicate, or are damaged for any reason,
diseases occur and many detrimental diseases are caused by unwanted protein-protein interactions.
Researchers are constantly studying causes for diseases and developing new methods to deliver
drugs are crucial for successful treatment.
Often, peptides are used to replicate a specific region of a protein that is known to be the
cause of the undesired interaction. Like proteins, peptides are composed of amino acids; however,
proteins are much larger molecules with larger complex structures. Researchers often look for the
active site of a protein, the region which interacts with another protein or is responsible for the
function of interest, and model peptide analog that may interact with the active site. The modeled
peptide can then be modified in many ways to study the interactions. Frequently fluorescent tags
are attached to the peptides in order to monitor interactions.
Bioconjugation is a very useful technology for labeling of biomolecules such as proteins,
DNA, and carbohydrates with fluorescent probes, affinity tags, or isotope labels.5-10 The labeled
biomolecules can then be used to study the function and to track the activity of a biomolecule. The
synthesis of these constructs requires chemoselective and site-selective bioconjugation reactions
that allow the formation of a covalent bond between two unique and chemically stable groups
under mild and aqueous conditions.
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Various techniques are known for bioconjugation but the most widely used methods are
the Cu-catalyzed click reaction of azides and alkynes11, the hydrazone and oxime ligations,12 the
Staudinger ligation,13 the Pictet-Spengler ligation,14 and native chemical ligation.15 Limitations of
these methods include the presence of toxic reagents and relatively slow reaction rates. Most
importantly, all of the chemoselective and site-selective bioconjugation methods that currently
exist use a stoichiometric amount of the chemical reagents. The need of a stoichiometric reagents
not only adds to expense to the method but also to the amount of chemical waste. In addition,
existing methods can lead to various byproducts and side reactions that add to the complexity of
the bioconjugation. A desired alternative in the field of chemical bioconjugation is a catalytic
approach that eliminates the need for stoichiometric amounts of chemical reagents.
Here we describe a new approach for site-selective bioconjugation, which will require the
use of a catalyst. Since biomolecules are involved, we propose to use non-toxic organocatalysts
for carrying out the bioconjugation rather than toxic metal catalysts. Besides the nontoxic nature
of organocatalysts there are also several other benefits over metal catalysts. The organocatalysts
have the potential for savings in cost, time and energy, are operationally simple, and reduce
chemical waste.16 Herein, we propose the use of organocatalysts for catalyzing a chemoselective
and site-selective bioconjugation reaction by undergoing a Henry reaction. This reaction occurs
between an aldehyde, or ketone, and a nitroalkane producing a nitroaldol compound. We chose to
exploit this reaction as there has been many techniques developed to obtain a carbonyl functional
group on biomolecules; however, there has yet to be any report on the Henry reaction being applied
to bioconjugation. The nitroaldol product will provide a hydroxyl and nitro functional groups
which can be exploited for conjugating tags, drugs, and probes to the biomolecule . This reaction
will enable selective conjugations of large molecules using an organocatalyst, opening an avenue
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to the synthesis of much larger, structurally defined molecules including multi-domain proteins,
protein−polymer conjugates,17 and oligomeric biomolecules.18
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1.1 Methods for Bioconjugation



Hydrazone and Oxime Ligation

As previously mentioned, there are several pathways in which to achieve bioconjugation.
Oximes and hydrazones have become of great interest for the achievement of bioconjugation as
the reaction can be performed under physiological conditions with water as a byproduct when
reacting a carbonyl containing moiety with an alkoxyamine or hydrazine (Figure 1). Due to their
facile ligation hydrazones and oximes have been utilized to form new probes and sensors,19,20
provide isotopic labeling of biomolecules,21 and to synthesize heterocycles.22-24 In recent years,
these reactions have also been fine-tuned to obtain faster reaction rates by incorporating catalysts
and performing these reaction in aqueous media to better suit biological applications.25
Although extensive research has improved the utility of these bioconjugates, the hydrolysis
of hydrazones and oximes in certain biological medium has been reported, with the former also
being hydrolyzed in cell cultures and plasma.26,27 The use of catalysts has proven to make reactions
more efficient, but there still remains concern about the toxicity of some of the catalysts.28
Therefore, there remains a need for the development of a method which can be performed under
biological conditions while also being able to withstand degradation by hydrolysis.

Figure 1: Synthesis of oxime or hydrazone from carbonyl reacted with alkoxylamine or hydrazine.

4



Pictet-Spengler

In order to combat the shortcomings of the hydrazone and oxime ligation, researchers have
developed new methodologies using modified Pictet-Spengler reactions.29 Many natural products
have been formed using the Pictet-Spengler reaction and researchers have chosen to exploit this
methodology in order to facilitate bioconjugation under physiological conditions. When the
traditional Pictet-Spengler reaction was performed the reaction proceeded slowly and required
acidic conditions which are not suitable for biological studies. By adding an aminooxy to the
tryptamine the reaction rate increased, except acidic conditions were still necessary (Figure 2b).30
Researchers continue to explore this pathway for bioconjugation by applying this method to
antibody drug conjugates (ADCs), to achieve target specific drug delivery, and an array of protein
and peptides moieties.

Figure 2: a) The traditional Pictet-Spengler ligation. b) The aminooxy Pictet-Spengler ligation
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Strain-Promoted Azide-Alkyne Cycloaddition

When designing a bioconjugation reaction method, researchers often think of means to
reduce toxicity by eliminating the need for metal catalysts, or utilizing organocatalysts which
produce more suitable for biorthogonal reactions. For these reasons, many biochemists have turned
away from the canonical copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC) and have
moved towards strain-promoted cycloadditions. These include the strain-promoted azide-alkyne
cycloaddition (SPAAC) and strain-promoted alkyne-nitrone cycloaddition reactions (SPANC)
(Figure 3).31 The advantages of utilizing SPANC over SPAAC is that the former method allows
for two R-functional groups in the nitrone comparison to the azide having only one R-group.
Additionally, SPANC has shown faster reaction rates and biocompatibility than SPAAC.32 These
two reactions allow for bioconjugation to occur without the need for a metal catalyst, thus reducing
cytotoxicity. One drawback from these two methods is slow rate of reaction due to the poor
reactivity of cyclooctyne,33 and much effort is still being invested into improving the reactivity of
these strained carbocycles. Additionally, the bulkiness of the cyclooctyne can cause perturbation
on protein structures making the protein inactive.

Figure 3: Two pathways for strain-promoted cycloaddition conjugation.
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Staudinger Ligation

The canonical Staudinger Ligation is an organic chemical reaction between an azide and a
phosphine. Recently, Bertozzi and co-workers chose this reaction to perform bioconjugation due
to the bio-orthogonal nature of both starting materials and it has since been applied to an array of
biopolymers.34 A modified approach to the Staudinger ligation has been developed by Bertozzi
and co-workers which allows for a more direct approach to bioconjugation in which phosphine
oxide is a byproduct; the reaction is termed “traceless” due to the amide bond having no residual
atoms (Figure 4).35 Overall, both methods are highly used in the synthesis of modified
biomolecules in applications such as protein engineering and nucleic acid labeling.36 Nonetheless,
both of these approaches require the incorporation of an azide in the biomolecule, which is a
synthetic challenge.

Figure 4: Two pathways for the Staudinger Ligation.

7



Native Chemical Ligation

The requirements for a Native Chemical Ligation (NCL) are that the biomolecule contain
a free N-terminus cysteine residue and the ligand contain a thioester. The reaction begin with a
thioester exchange between the two moieties which results in thiol being removed. It then
undergoes a transthioesterification step resulting in a cysteine residue being present at the ligation
site (Figure 5).15 This method produces high yields, is irreversible, and occurs in aqueous media.
The major drawback from this method is the requirement of a free N-terminus cysteine residue.
Cysteine is usually found participating in disulfide bridges in proteins and is also one of the least
abundant amino acids. Thus resulting in limited applicability with this method.

Figure 5: Native Chemical Ligation reaction.
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1.2 Organocatalyst and the Henry Reaction

The concept of organocatalysis has quickly gained popularity in synthetic biology due to its
“green-chemistry” potential as it replaces the need for using metal catalysts.37 Organocatalyst are
organic molecules that do not possess metals and are capable of increasing the rate of a chemical
reaction. This reasoning also plays a role on its importance in biological reactions due to the toxic
effects of some metals. One synthetic reaction that has successfully been accomplished through
the use of organocatalysis is the Henry reaction. It has been reported that through the use of
enantiomerically pure guanidines, reactions have produced products with up to 95 % of
enantiomeric excess.38 This report became interesting as this method has yet to be applied to
biological reactions.
The Henry reaction requires a nitroalkane reacting with either an aldehyde or a ketone yielding
a nitroaldol product. There have been many reports on how to convert the N-terminus residues of
peptides or proteins into aldehydes or ketones in order to undergo bioconjugation; however, this
method has yet to be applied for attaining bioconjugation through the Henry reaction. Thus, we
felt the need to explore this pathway as its success would be of great use in the fields of medicine
and pharmaceutics. The nitroaldol product would result in the biomolecule containing two possible
functional handles which can be reacted to conjugate with other biomolecules, drugs, tags, or
peptides. Furthermore, if this method is applied for antibody drug conjugation (ADC), the antibody
could possibly carry a drug while carrying a tag or marker which researchers can track to ensure
target-specific delivery.
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Chapter 2: Organocatalyzed Henry Reaction for Bioconjugation

2.1 Results and Discussion

To begin this investigation, we designed an amino acid aldehyde as the model aldehyde for
optimizing the Henry reaction. We chose to synthesize a phenylalanine aldehyde 1 to undergo
preliminary reactions and monitored the reaction using HPLC (Scheme 1). The procedure for
synthesizing phenylalanine aldehyde can be found in Section 2.3.

Scheme 1: General reaction for synthesizing the phenylalanine aldehyde moiety.

The first reaction was set using the phenylalanine aldehyde and nitromethane with proline
as the catalyst using 100mM phosphate buffer pH 7.5 as solvent (Scheme 2). Proline was chosen
as the initial organocatalyst for this reaction due to its wide application as an organocatalyst in the
literature along with its availability in our lab. Nitromethane was chosen as the model nitroalkane
for the Henry reaction due to of its simple structure and because it would provide sufficient
information as to whether this methodology is feasible. The reaction was set for 24 h and was
analyzed using HPLC and LCMS. Although the reaction yielded product, the reaction was not
complete as there still remained unreacted phenylalanine aldehyde in the reaction mixture. Upon
analyzing the fractions by LCMS, it was noted that product, 3, underwent condensation to 4
10

followed by a Michael addition of a second nitromethane molecule 5 resulting in 52% conversion
of the Michael addition (Scheme 3). It was difficult to account for how much starting material, 1,
Henry reaction product, 3, and condensation product, 4, remained in the reaction as these three
coeluded on the HPLC (Supporting Information Figure S6). Therefore, percent conversions were
calculated and reported only for the Michael addition product.

Scheme 2: Proposed Henry reaction using organocatalysis.

Scheme 3: a) Condensation and b) Michael addition mechanism.

Upon attaining these results different catalysts readily available in our lab were screened
to achieve higher yields (Table 1). All reactions were completed with 100 mM phosphate buffer,
and were incubated at 37 ºC and with 90 RPM. Reactions were monitored after 6 h by HPLC and
LCMS (see Supporting Information). As a control, two reactions were set, one without the use of
any catalyst and after 6 h only 5 % conversion of product was detected. For the second control
reaction we chose to use DIEA (N,N-diisopropylethylamine), in place of a catalyst since the Henry
reaction is a base driven reaction, however only 32 % conversion to product, 5, was observed as
well as another product which was unidentified (Supporting Figure S8). Although the Henry
11

reaction is a base driven reaction, under our reaction conditions poor conversion was acquired
when using a base. We then chose to use N,N-Diphenylthiourea as an organocatalyst after seeing
organic synthesis reports of thiourea being utilized to catalyze the Henry reaction. 38 Nonetheless,
we only observed a 10 % conversion. Next, we sought to utilize amino acids and amino acid
derivatives as organocatalysts due to their availability in our lab and compare them to the results
previously observed with proline. Glycine methyl ester, proline, and threonine resulted in low to
moderate conversions (Table 1). Although threonine showed promising results, 80 % conversion,
it also produced undesired products which were not identifiable. When glycine was used we
observed 86 % conversion with the least amount of side product and was thus chosen as the catalyst
for the remainder of the research project (Scheme 4).

Scheme 4: Proposed reaction mechanism.

Table 1: Percent conversion calculated for Michael addition product as determined by HPLC.
Entry
1
2
3
4
5
6
7

Catalyst
None
Proline
Glycine
Threonine
DIEA
Glycine methyl ester
N,N,-Diphenylthiourea

12

% Conversion
5
44
86
80
32
22
10

Following the catalytic studies we determined that in order to deem this reaction suitable
for biological systems it was crucial to perform pH studies on the reaction system. The reaction
was subsequently repeated using glycine as the catalyst and 100 mM phosphate buffers at pH 4.5,
7.5, and 10.5. We found that the reaction occurred as previously observed under acidic and neutral
conditions; however, when the reaction was set under basic conditions the reaction produced
unforeseen side products (Supporting Figure S13). With these results we were satisfied to proceed
with peptide studies and eventually protein models using glycine as the catalyst (7.5 X 10-4 mmol)
using phosphate buffer pH 7.5 as the solvent and nitromethane as the nitroalkane for the Henry
reaction.
After determining the catalyst and reaction pH, two tripeptides, Ser-Ala-Phe and Ser-ValPhe, were synthesized through the well-known solid-phase-peptide-synthesis method (SPPS).39
Upon synthesizing, cleaving, and purifying the peptides (see Section 2.3 for procedure) the Nterminus serine was modified to yield an aldehyde through sodium periodate oxidation on each of
the peptides (Scheme 5).40 Peptide aldehydes were purified by HPLC and analyzed through MS
(see Supporting Information). Peptide Ser- Ala- Phe and Ser-Val-Phe aldehyde were subsequently
reacted with nitromethane using glycine as the organocatalyst for the reactions. Surprisingly, the
peptide aldehydes were consumed in 30 min with > 99 % conversion yield to a mixture of Henry
product, condensation product, and Michal addition product eluding in the same peak on the HPLC
(Supporting Figure S14). After 6 h the reaction still contained a mixture of products. We attribute
the fast consumption of aldehyde in peptides as compared to the phenylalanine aldehyde adduct
used previously to steric. The peptides were linear and the aldehyde was able to freely react;
whereas in the phenylalanine aldehyde adduct, the aldehyde had the bulk of the molecule in orthoposition in the phenyl ring.

13

Scheme 5: Modification of peptide to peptide aldehyde through sodium periodate oxidation.

There have been reports of proteins with the N-terminus glycine being converted into
aldehydes through the use of pyridoxal 5′-phosphate (PLP).41 Myoglobin is a commercially
available protein which contains an N-terminus glycine and we had previously successfully
converted the N-terminal glycine to an aldehyde; therefore, we chose to apply our preliminary
findings to myoglobin. The MS of myoglobin was taken prior to experimental procedures (Figure
6) and myoglobin was subsequently modified to contain an N-terminus aldehyde (Scheme 6,
Figure 7) and reacted with nitromethane using a glycine catalyst in 100mM phosphate buffer pH
7.5 for 3 h at 37 ºC stirring at 90 RPM (Scheme 7). The reaction was then analyzed by MS (Figure
8). Although the MS of the myoglobin Henry reaction show background interference product was
still observed. Further work and analysis are still required for the completion of this work;
however, the preliminary work reported here demonstrates the possibility of applying this
methodology for bioconjugation in the future.

14

Figure 6: MS of unmodified myoglobin.

Scheme 6: N-terminus glycine modification of protein to form aldehyde.
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Figure 7: MS of myoglobin aldehyde.

Scheme 7: Organocatalyzed Henry reaction of myoglobin aldehyde with nitromethane.
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Figure 8: Myoglobin aldehyde reaction with nitromethane MS.
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2.2 Future Work
Overall, this work highlights the potential of applying the well-known Henry reaction to
bioconjugation using simple amino acids as catalyst. This method resulted in yields of up to 86 %
conversion in mild conditions which is suitable for biological systems. Additionally, by using the
Henry reaction the biomolecule is equipped with new functional handles which can be exploited
for conjugating a drug or tag.
Further investigation is needed to characterize the final products and to determine the
stereo-selectivity of the organocatalyst by using 1H and 13C NMR for the phenylalanine aldehyde
Henry product 3, 4, and 5, as well as the peptides moieties. Myoglobin, myoglobin aldehyde, and
the final myoglobin Henry product needs to be characterized for its secondary structure through
the use of CD-spectrometry to demonstrate that the protein will still remain active after
modification. Lastly, we hope to be able to apply this methodology to antibody-drug-conjugates
(ADCs) in order to facilitate target drug deliveries.

18

2.3 Instrumentation, Conditions, and Materials.

Fmoc-amino acids were obtained from Nova Biochem (EMD Millipore Corporation)
(Billerica, Massachusetts) and CreoSalus (Louisville, Kentucky). Rink amide was obtained from
ChemPep Inc. (Wellington, Florida). N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium
hexafluorophosphate (HBTU) was obtained from CreoSalus (Louisville, Kentucky). N,N′Disuccinimidyl carbonate (DSC) was obtained from Nova Biochem, under (EMD Millipore
Corporation) (Billerica, Massachusetts). 4-Dimethylaminopyridine (DMAP): Merck KGaA
(Darmstadt, Germany). N,N-Dimethylformamide (DMF): Macron Fine Chemicals (Center Valley,
Pennsylvania). Dichloroethane (DCE), acetonitrile, N,N- Diisopropylethylamine (DIEA), N,N'diisopropylcarbodiimide (DIC), 1-Hydroxy-7-azabenzotriazole (HOAt), were purchased from
(EMD Millipore Corporation)(Billerica, Massachusetts). Piperidine was purchased from Alfa
Aesar (Ward Hill, Massachusetts). Trifluoroacetic acid (TFA) was purchased from VWR 100
Matsonford RoadRadnor, PA. Diethyl Ether: Sigma Aldrich (St. Louis, Missouri). Water was
purified using a Millipore Milli-Q water purification system.
All commercial materials (Aldrich, Fluka, Nova) were used without further purification.
All solvents were reagent grade or HPLC grade (Fisher).

Anhydrous THF, diethyl ether,

dichloromethane, and DMF were obtained from Aldrich and Fluka.


NMR.
Proton NMR spectra were acquired at 25 °C in DMSO-d6 using an Agilent DD2

(600 MHz) spectrometer and carbon NMR spectra on a 151 MHz equipped with a 3 mm
He HCN cryoprobe from Merck. All NMR chemical shifts (δ) are referenced in ppm
relative to residual solvent or internal tetramethylsilane. 1H NMR chemical shifts
referenced to residual DMSO-d5 at 2.50 ppm, and 13C NMR chemical shifts referenced to
19

DMSO-d6 at 39.52 ppm. Carbon NMR spectra are proton decoupled. NMR spectral data
are reported as chemical shift (multiplicity, coupling constants (J), integration).
Multiplicity is reported as follows: singlet (s), broad singlet (bs), doublet (d), doublet of
doubles (dd), doublet of triplet (td), triplet (t) and multiplet (m). Coupling constant (J) in
Hertz (Hz).


Analytical HPLC.
Analytical HPLC chromatography (HPLC) was performed on an Agilent 1100

series HPLC equipped with a 4.6 mm C-18 reversed-phase column. All separations
involved mobile phase of 0.1 % FA (v/v) in water (solvent A) and 0.1 % FA (v/v) in
acetonitrile (solvent B). Peptide compositions were evaluated by analytical reverse phase
HPLC using a gradient of 0.1 % FA in acetonitrile versus 0.1 % FA in water. Analytical
HPLC method using a linear gradient of 0 – 80 % 0.1 % FA (v/v) acetonitrile in 0.1 %
aqueous FA over 30 min at room temperature with a flow rate of 1.0 mL min-1. The eluent
was monitored by absorbance at 220 nm unless otherwise noted.


HRMS
HRMS data were acquired on a Q-ToF mass spectrometer using positive polarity

electrospray ionization (+ESI). Tandem MS experiments were performed using collision
induced dissociation (CID) with N2 as the collision gas.
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LCMS
Mass spectrometry was performed using ultra high performance liquid

chromatography-mass spectrometry using the Agilent 1100 Series LCMSD VL MS
Spectrometer.
Instrument: Agilent 1290 UHPLC with 6520 Q-ToF | Mass Range: m/z 150 to 3200 |
Ionization: (+) ESI | Voltages: capillary = 3.5 kV, fragmentor = 175 V, skimmer = 65 V|
Drying Gas: N2 at 300 °C | Nebulizer: N2 at 35 L/min | Acquisition Rate: 1 spectra/s |
Flow Rate: 0.1 mL/min | Injection Volume: 15 mL | Mobile Phase: A = 0.1% formic acid
in water; B = acetonitrile | Gradient: 15 % B to 50 % B in 55 minutes, followed by 5 min
re-equilibration time | Column: Acquity UPLC Peptide BEH C18, 300 Å, 1.7 mm, 1.0 X
150 mm | Column Temp.: 50 °C | Deconvolution using maximum entropy algorithm in
Masshunter software.


LC-MS conditions
Analysis was performed on an ultra-performance LC system (ACQUITY, Waters

Corp., USA) coupled with a quadrupole time-of-flight mass spectrometer (Q-ToF Premier,
Waters) with electrospray ionization (ESI) in positive mode using Mass lynx software
(V4.1). 5 µL of the sample was injected onto a C4 column (Phenomenex Aeris™ 3.6 µm
WIDEPORE C4 200 Å, LC Column 50 x 2.1 mm) with a 200 µL/min flow rate of mobile
phase of 95 % H2O, 5 % acetonitrile and 0.1 % formic acid (solution A) and 95 %
acetonitrile, 5 % H2O, and 0.1 % formic acid (solution B) beginning gradient time - 0 min
10 % B; 5 min 28 % B; 20 min 38 % B; 22 min 100 % B. Capillary voltage was set at 3.0
kV, the sample cone voltage was 50 V, and the extraction cone was 4.0 V. The source and
desolvation temperature were maintained at 95 and 300 °C, respectively, with the
21

desolvation gas flow at 400 L/h. The Time of Flight Mass Spectrometry (TOF/MS) scan
was 1 s long from 100 to 1100 m/z with a 0.02 s inter-scan delay using extended dynamic
range acquisition and centroid data format. The lock mass was used to correct instrument
accuracy with a 0.5 µM solution of HP 1221 (Agilent part number G196985003). Ion
source parameters such as the source temperature (gas and sample cone), mobile phase
flow rate, and cone voltage were fixed throughout the study.

22

2.4 Experimental Procedures



Synthesizing Phenylalanine Aldehyde
To prepare phenylalanine aldehyde, formylphenoxy acetic acid (2.1 mmol) was

dissolved in 3 mL of acetonitrile (3 mL) along with DCC (2.4 mmol) and N-hydroxy
succinimide (2.3 mmol) in a round bottom flask with a stir bar and left stirring for 3 h.
Reaction was filtered with vacuum to remove urea formed within the reaction. The solvent
was removed and reaction was dried until formyl phenoxy NHS ester solid was recovered.
The crude solid was recrystallized using THF; upon crystallization the crystals were then
dried overnight under vacuum. 1H and 13C NMR analysis confirmed formation of formyl
phenoxy NHS ester. 1H NMR (600 MHz, DMSO-d6) δ 10.42 (s, 1H), 7.74 (dd, J = 7.7,
1.8 Hz, 1H), 7.69 (ddd, J = 8.9, 7.3, 1.9 Hz, 1H), 7.27 (d, J = 8.4 Hz, 1H), 7.18 (t, J = 7.5
Hz, 1H), 5.55 (s, 2H), 2.83 (s, 4H). 13C NMR (151 MHz, DMSO-d6) δ 188.8, 169.9, 165.2,
159.3, 136.2, 127.9, 124.8, 122.2, 114.1, 63.7, 25.5.
Formyl phenoxy NHS ester (0.65 mmol) was then dissolved by anhydrous DMF (2 mL) and
DIEA (280 µL) in round bottom flask along with L-Phenylalanine methyl ester and stirred at room
temperature for 4 h. Once again solvent was removed by vacuum. Column chromatography was
utilized to purify phenylalanine aldehyde product and was analyzed by MS and 1H and 13C NMR.
1

H NMR (600 MHz, DMSO-d6) δ 10.40 (s, 1H), 8.59 (d, J = 8.1 Hz, 1H), 7.74 (dd, J = 7.7, 1.9

Hz, 1H), 7.59 (ddd, J = 8.8, 7.3, 1.9 Hz, 1H), 7.32 – 7.23 (m, 2H), 7.23 – 7.18 (om, 3H), 7.12 (t, J
= 7.5 Hz, 1H), 6.98 (d, J = 8.4 Hz, 1H), 4.70 (d, J = 14.9 Hz, 1H), 4.63 (d, J = 14.9 Hz, 1H), 4.63
– 4.53 (om, 1H), 3.64 (s, 3H), 3.13 (dd, J = 13.8, 5.1 Hz, 1H), 3.00 (dd, J = 13.8, 9.8 Hz, 1H). 13C
NMR (151 MHz, DMSO-d6) δ 189.7, 171.6, 167.4, 159.7, 137.1, 136.1, 129.1, 128.2, 128.1, 126.6,
124.4, 121.4, 113.6, 67.0, 53.2, 52.0, 36.3. HRMS (+ESI) C19H20NO5+: 342.1336, found 341.9.
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Phenylalanine Aldehyde Henry Reaction
For the organocatalyzed Henry reaction, phenylalanine aldehyde (0.003 mmol) was

dissolved with 100 µL of 50:50 mixture of DMSO and 100 mM phosphate buffer (pH 7.5) in a dry
and clean vial. After dissolving the phenylalanine aldehyde, an additional 400 µL of 100 mM
phosphate buffer (pH 7.5) was added to the solution. A stock solution of the catalyst was prepared
to accurately deliver the catalyst (7.5 x 10-4 mmol). The catalyst was pipetted to the dissolved
phenylalanine aldehyde solution. Lastly, nitromethane (0.036 mmol) was added to the reaction
mixture and the vial was placed in an incubator at 37 ºC and set to 90 RPM.


Synthesizing Peptide Aldehydes
Peptides with serine at the N-terminus (0.014 mmol) were dissolved with 1200 µL of 50 mM

phosphate buffer (pH 7.5). Sodium periodate (0.071 mmol) was added to the solution and stirred
at room temperature for 3 h. Unreacted sodium periodate was filtered out of the solution and
peptide aldehydes were purified by HPLC and mass confirmed through LCMS (Figure S14 and
S15).


Peptide Aldehyde Henry Reaction
Peptide aldehyde (0.003 mmol) was dissolved in 500 µL of 100 mM phosphate buffer (pH

7.5). A stock solution of the catalyst was prepared to accurately deliver the catalyst (7.5 x 10-4
mmol). The catalyst was pipetted to the dissolved peptide aldehyde solution. Lastly, nitromethane
(0.036 mmol) was added to the reaction mixture and the vial was placed in an incubator at 37 ºC
and set to 90 RPM. Reaction was purified by HPLC and mass confirmed through LCMS (Figure
S14 and S15).
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Fmoc Solid-Phase Peptide Synthesis
Peptides were synthesized manually on a 0.25 mmol scale using Rink amide resin.

Fmoc–group was deprotected with 20% piperidine–DMF for 20 min to obtain a
deprotected peptide-resin. Fmoc-protected amino acids (1.25 mmol) were coupled on the
resin using a HBTU (1.25 mmol) and DIEA (1.25 mmol) for 2 h at room temperature.
Peptides were synthesized using standard protocols and were cleaved from the resin using
a cocktail of trifluoroacetic acid: triisopropyl silane: water (95: 2.5: 2.5, respectively) for
2 h. The resin was removed by filtration and the resulting solution was concentrated. The
oily residue was triturated with diethyl ether to obtain a white suspension. The resulting
solid was dissolved in acetonitrile/water mixture and purified by HPLC.


Converting N-terminus Glycine to Aldehyde in Proteins
Myoglobin (3.0 x 10-4 mmol) was dissolved in sodium phosphate buffer (25 mM, pH 6.5).

A stock solution of PLP was prepared by dissolving PLP (0.021 mmol) in 1 mL of sodium
phosphate buffer (25 mM, pH 6.5) and adding 24 µL of NaOH solution (1 M) and vortexing. A
microelectrode was used to ensure the pH of the stock solution remained at pH 6.5. The dissolved
protein and PLP stock solution were combined in a 1:1 ratio by volume and incubated at 37ºC for
4 h. The protein and protein aldehyde were analyzed by ultra-performance LC coupled with a
quadrupole time-of-flight mass spectrometer (Supporting Information).
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Chapter 3: Supporting Information

3.1 1H NMR , 13C NMR, and MS

Figure S1: 1H NMR of formylphenoxy NHS ester.
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Figure S2: 13C NMR of formylphenoxy NHS ester.
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Figure S3: 1H NMR of phenylalanine aldehyde.
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Figure S4: 13C NMR of phenylalanine aldehyde.
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3.2 HPLC and LCMS Traces
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Molecular Weight: 341.36

Figure S5: a) HPLC and b) LCMS traces of phenylaldehyde aldehyde.

a)

c)

b)

d)

Figure S6: a) HPLC of phenylalanine reaction with nitromethane using proline as catalyst; b)
LCMS traces of crude phenylalanine reaction with nitromethane using proline as catalyst; c)
LCMS of 17.7 min peak; d) LCMS of 20 min peak; 24 h reaction.
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a)

b)

Figure S7: a) HPLC of phenylalanine reaction with nitromethane control reaction; b) LCMS traces
of crude control reaction; 6 h reaction.

c)

b)

a)

Figure S8: a) HPLC of phenylalanine reaction with nitromethane using DIEA as catalyst; b)
LCMS of 17.7 min peak; c) LCMS of 20 min peak; 6 h reaction.
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a)

b)

c)

Figure S9: a) HPLC of phenylalanine reaction with nitromethane using N,N-Diphenylthiourea as
catalyst; b) LCMS of 17.7 min peak; c) LCMS of 20 min peak; 6 h reaction.

a)

c)

b)

Figure S10: a) HPLC of phenylalanine reaction with nitromethane using glycine methyl ester as
catalyst; b) LCMS of 17.9 min peak; c) LCMS of 20 min peak; 6 h reaction.
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a)

b)

c)

Figure S11: a) HPLC of phenylalanine reaction with nitromethane using threonine as catalyst; b)
LCMS of 17.9 min peak; c) LCMS of 20 min peak; 6 h reaction.

a)

b)

c)

Figure S12: a) HPLC of phenylalanine reaction with nitromethane using glycine as catalyst; b)
LCMS of 17.9 min peak; c) LCMS of 20 min peak; 6 h reaction.
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a)

b)

c)

Figure S13: HPLC of phenylalanine reaction with nitromethane using glycine as catalyst under
different pH conditions. a) reaction under acidic condition, pH 3.5 b) reaction under biological
condition, pH 7.5; c) reaction under basic condition, pH 10.5.

a)

b)

c)

Figure S14: HPLC of SVF. a) SVF peptide b) SVF peptide aldehyde c) SVF product of
nitromethane reaction using glycine as catalyst; 30 min.
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a)

b)

c)

Figure S15: LCMS of SVF. a) SVF peptide; b) SVF peptide aldehyde; c) SVF product of
nitromethane reaction using glycine as catalyst.

a)

c)

b)

Figure S16: LCMS of SAF. a) SAF peptide; b) SAF peptide aldehyde; c) SVF product of
nitromethane reaction using glycine as catalyst.
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